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Introduction: Registration of clinical trials has been initiated in order to
assess adherence of the reported results to the original trial protocol. This study
aimed to investigate the publication rates, timely dissemination of results, and
the prevalence of consistency in hypothesis, sample size, and primary endpoint
of Dutch investigator-initiated randomized controlled clinical trials (RCTs).
Methods: All Dutch investigator-initiated RCTs with a completion date
between December 31, 2010, and January 1, 2012, and registered in the Trial
Register of The Netherlands database were included. PubMed was searched for
the publication of these RCT results until September 2016, and the time to the
publication date was calculated. Consistency in hypothesis, sample size, and
primary endpoint compared with the registry data were assessed.
Results: The search resulted in a total of 168 Dutch investigator-initiated
RCTs. In September 2016, the results of 129 (77%) trials had been published, of
which 50 (39%) within 2 years after completion of accrual. Consistency in
hypothesis with the original protocol was observed in 108 (84%) RCTs; in 71 tri-
als (55%), the planned sample size was reached; and 103 trials (80%) presented
the original primary endpoint. Consistency in all three parameters was
observed in 50 studies (39%).
Conclusion: This study shows that approximately one out of four Dutch
investigator-initiated RCTs remains unpublished 5 years after initiation. The
observed low overall consistency with the initial study outline is a matter of con-
cern and warrants improvements in trial design and assessment of trial feasibility.
1 | INTRODUCTION
The declaration of Helsinki (1964) is the cornerstone of
modern human research ethics. Based on the fundamen-
tal principle of respect for the individual and the right to
take informed decisions regarding participation in
research, the declaration morally binds physicians and
scientists to publish clinical trial information and
results.1 It has been estimated that only half of the one
million trials started since 1948 have been published.2
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Patients who give informed consent to participate
in scientific research and thereby agree to exposure to
an experimental treatment do so under the assumption
that they contribute to medical science. If investigators
fail to publicly communicate these results, this contribu-
tion is nullified and the conditions for the initial agree-
ment for participation are not met. This implies that
invaluable information for the selection of optimal treat-
ment and for the allocation of future research funds are
withheld from the scientific community. This also
results in loss and distortion of evidence, impairment of
the practice of evidence-based medicine, and a potential
waste of funds on duplicative trials. Failure to publish
research results has been considered as scientific
misconduct.3,4
The validity of clinical trial results starts with a care-
fully designed and conducted trial. Adherence to the trial
protocol in the eventual trial report is essential in mini-
mizing bias and prevention of selective reporting.
Reporting of results based on outcomes or any specific
interest of the investigator will increase the risk of bias
and potentially hampers evidence-based medicine.
Unfortunately, discrepancies between a registered trial
protocol and its publication are still frequently
reported.5-8
Since July 2005, the International Committee of Med-
ical Journal Editors requires trials to be registered before
the enrolment of the first patient in order to prevent
selective publication of trial outcomes in an effort to
reduce this form of publication bias.9 Besides the obliga-
tion to publish trial results, it is essential that these
results become available within an appropriate period to
ensure that clinical decisions can be made on the most
recently available evidence. However, since 2005, several
reports have shown that between 25% and 50% of the
clinical trials experience significant delay or even remain
unpublished.8,10-16 The tendency to publish only positive
results is just one of the reasons many trials remain
unpublished.17
Even though academic medical centers are at the
heart of clinical research, their publishing and reporting
of results are not optimal.14,16,18,19 In The Netherlands,
there is an excellent track record of investigator-initiated
clinical research that is considered because of a well-
organized research infrastructure in which academic and
general hospitals are actively participating.20
This study aims to investigate the rates of publication
of trial results within 2 years after planned completion or
premature closure of patient accrual. The prevalence of
consistency in hypothesis, sample size, and primary end-
point between the registry and the corresponding publi-
cation of Dutch investigator-initiated randomized
controlled trials (RCTs) was investigated.
2 | METHODS
In August 2016, information of all RCTs registered in the
prospective Trial Registry in The Netherlands (NTR),
which is part of the WHO primary registries, was col-
lected. To ensure an adequate period allowing researchers
to publish their results by August 2016 (ie, 5 years after
data completion), only RCTs with a reported completion
date between December 31, 2010, and January 1, 2012,
were included. To identify all RCTs with a responsible
party based at a Dutch academic medical center, the
“SPONSOR/INITIATOR” field of the NTR was used. All
RCTs that had one of the eight Dutch academic medical
centers submitted in this field were selected for analysis.
Multicenter and multinational trials were included only
if a Dutch academic center had initiated the trial. Of
every RCT the sample size, the study design (single or
multicenter design), and the studied condition according
to the clinicaltrials.gov categories were collected.
The outcome parameters included the number of
published RCTs, the number of RCTs with published
results within 2 years after completion of patient accrual,
and the consistency between the trial registry data and
published data that was scored in respect of the main
hypothesis, sample size, and primary endpoint.
2.1 | Search strategy to identify
publication of RCTs
The PubMed service was used to search the biomedical lit-
erature for publication using the unique registration num-
bers of the RCTs between January 2011 and September
2016 by two reviewers (BK and JH). If no publication was
identified, the search was expanded with details of the reg-
istered trial, such as author, acronym, primary outcome,
scientific title, and hypotheses. Finally, if still no publica-
tion was found, the principal investigators of the study
were contacted by email. A reminder was sent to every
contact person that did not respond to the first email
within 1 week. If no publication was found, and if the
principal investigators did not reply to either email, it was
assumed that the trial results had not been published.
The earliest publication of an RCT reporting the main
results including the primary endpoint was selected. If
multiple primary endpoints were registered, the earliest
publication reporting at least one of the primary end-
points was used to assess the time to publication. All arti-
cles were retrieved by BK, and a second reviewer JH
independently reviewed all selected articles. Any uncer-
tainties were discussed until consensus was reached. In
case BK was not able to identify the publication of a reg-
istered RCT, a second search was performed
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independently by JH. The time to publication curve was
generated using the Kaplan-Meier method.
2.2 | Data selection of published trials
Full copies of all identified articles were obtained, and
the time span in months between the completion date
and the publication date was calculated using the “com-
pletion date” field of the NTR database and the publica-
tion date. For RCTs with an earlier online publication
date (ePub date), the ePub date was used as the publica-
tion date. The following variables were collected from the
available publications: the hypothesis, sample size, and
the primary outcome.
2.3 | Assessment of consistency:
Comparison of publications with their
protocol
All retrieved corresponding publications of registered
RCTs were used for the consistency assessment. Consis-
tency in hypothesis was assessed by comparing the pri-
mary hypothesis provided in the NTR with the
hypothesis in the published article. When a hypothesis
was not provided in the NTR, that RCT was recorded as
discrepant in hypothesis for the analysis.
In case multiple primary endpoints were registered,
an RCT was only considered consistent in primary end-
point if all primary endpoints were published and no
new primary endpoints were provided in the publication.
The primary endpoint was also considered discrepant if it
was not reported in the NTR.
It is mandatory in the NTR to register the sample size
of a trial. The sample size calculation was considered dis-
crepant if the sample size calculation of the publication
differed from the NTR. When no sample size calculation
was provided in the publication, and the recruited num-
ber of patients did not differ more than 5% from the regis-
tered sample size, the trial was considered consistent in
sample size calculation.
If a published hypothesis, primary endpoint, and/or
sample size showed discrepancy with the information as
registered in the NTR, but a transparent and clearly formu-
lated explanation for the deviation was provided in the pub-
lication, the RCT was considered consistent on this issue.
3 | RESULTS
Between December 31, 2010, and January 1, 2012, a total
of 168 RCTs sponsored by a Dutch academic center were
registered in the NTR. These 168 RCT had a total sample
size of 55.821 patients (median 120, IQR 50-264). Among
the 168 RCTs, 67 (40%) had a multicenter design and
87 (52%) were planned to enroll more than 100 patients.
Nutritional and metabolic disorders (18%), disorders in
behavior (18%), cancer and other neoplasms (11%), and
cardiovascular diseases (11%) were the most frequently
studied conditions. Additional RCT characteristics are
summarized in Table 1.
3.1 | Publication of results
In total, 129 (77%) out of 168 RCTs were published in a
medical journal as of October 2016 with a median time to
publication of 30 months (IQR 19-43). An overview of the
publication rate of RTCs is shown in Figure 1. Publica-
tion rates varied between the leading academic centers,
ranging from 67% to 94%. The rates of RCTs published
within 24 months ranged between 20% and 39%
(Table 1). In addition, the differences in time to publica-
tion between study topics were displayed in Figure 2.
A large variety in time between the completion and
publication date of an RCT was observed. Results of
50 (30%) RCTs were published within 24 months, and
results of 79 RCTs (47%) were published more than
24 months after the completion date. Results of five (4%)
RCTs were published before their closing date.
Of the 39 (23%) RCTs that were not published,
21 principal investigators responded to our emails. Of
one RCT, contact information could not be found in the
NTR, which leaves 18 (11%) of the 168 RCTs without any
information on publication. The principal investigators
who replied to our email indicated that eight RCTs were
never published because the RCT had been prematurely
discontinued or had never been initiated. Of the six
RCTs, it was indicated that the conduct had been del-
ayed, and consequently, publication was delayed. Con-
tacts of four RCTs responded that the manuscript of their
RCT was rejected by journals for publication. One princi-
pal investigator was in the process of writing the manu-
script, and one replied that his PhD student had left, and
therefore, the RCT was never published.
3.2 | Consistency in hypothesis, primary
endpoint, and sample size
Consistency in all three parameters was observed in
50 (39%) of the 129 published RCTs. In 108 RCTs (84%),
consistency in the main hypothesis was observed. In
total, 10 RCTs did not report a hypothesis in the NTR
and were assessed as discrepant. Consistency of the
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published RCT in the primary endpoint was observed in
103 RCTs (80%) and in sample size in 71 RCTs (55%). In
six RCTs (5%), no sample size calculation was provided
in the publication, but the number of recruited patients
was within 5% range from the registered sample size.
Additional details on consistency in hypothesis, sample
size, and primary endpoint are summarized in Table 2.
In 32 of the 58 RCTs that were discrepant in sample
size calculation, the calculated sample size differed from
the registered sample size without an explanation. In
26 of the 58 RCTs that were discrepant in sample size cal-
culation, no sample size calculation was provided in the
publication and the recruited number of patients differed
more than 5% of the registered sample size.
TABLE 1 Overall characteristics and dissemination of randomized controlled trials across Dutch academic centers (completion date
between December 31, 2010, and January 1, 2012)
Trials
Registered N
Overall Rate of
Publication N (%)
Median Time From
Completion Date to
Published Results in
Months (IQR)
Rate of Results Published
≤24 months of Study
Completion Date N (%)
Total 168 129 (77) 30 (19-43) 50 (20)
Center
I 29 24 (83) 29 (16-41) 9 (31)
II 28 21 (75) 24 (21-43) 11 (39)
III 16 15 (94) 22 (10-45) 4 (25)
IV 24 17 (71) 25 (15-48) 9 (38)
V 21 15 (71) 25 (15-47) 7 (33)
VI 10 8 (80) 33 (22-44) 2 (20)
VII 13 11 (85) 44 (27-53) 2 (15)
VIII 27 18 (67) 32 (19-42) 6 (22)
Study sites
Multicenter 68 51 (75) 33 (18-52) 18 (35)
Single center 100 78 (78) 29 (19-40) 32 (41)
Number of enrolled patients
≤100 80 62 (78) 30 (18-46) 22 (35)
>100 88 67 (76) 31 (19-43) 28 (42)
Conditions studied
Nutritional and metabolic
disorders
30 24 (80) 28 (15-36) 11 (46)
Behavior disorders 30 23 (77) 25 (16-36) 11 (48)
Cardiovascular diseases 19 14 (74) 29 (18-34) 5 (36)
Cancer and other
neoplasms
19 16 (84) 27 (21-35) 7 (44)
Nervous system diseases 10 7 (70) 47 (19-55) 3 (43)
Muscle, bone, and
cartilage diseases
9 6 (67) 32 (12-46) 2 (33)
Conditions of the urinary
tract, sexual organs,
and pregnancy
9 6 (67) 47 (33-58) 0 (0)
Wounds and injuries 7 7 (100) 48 (39-59) 1 (14)
Viral diseases 5 5 (100) 36 (25-53) 1 (20)
Respiratory tract diseases 4 1 (25) 32 (32-32) 0 (0)
Infectious diseases 4 2 (50) 15 1 (50)
Digestive system diseases 3 2 (67) 36 1 (50)
Others 19 16 (84) 33 (20-45) 7 (44)
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Of the 129 reported RCTs, 57 (44%) recruited 90% or
less than the registered planned sample size. Of these
57 trial reports, 29 (22%) did not report a clear explana-
tion for this lower accrual.
Overall consistency as well as consistency in two,
one, or even none of the parameters varied between aca-
demic centers ranging from 14% to 50% (Figure 3). Three
RCTs demonstrated a discrepancy in all three parame-
ters. There were some differences in consistency between
topics, for instance, a low sample size consistency (30%)
in RCTs on behavioral conditions.
The ideal trial registration is completed before the
inclusion of the first patient. In this study, 68 (40%) out of
the 168 trials had a registration date after the first inclu-
sion date. There were no differences in trial characteris-
tics between trials registered before or after the first
inclusion and no differences in consistency parameters
between the published trials.
4 | DISCUSSION
A publication rate of 77% among 168 Dutch investigator-
initiated RCT within 5 years after the completion of
patient accrual of the RCT was observed. Median time to
publication was 30 months (IQR 19-43), and only 30%
(50/168) of the results were published within 2 years after
the completion date. A low overall consistency in hypoth-
esis, sample size calculation, and primary endpoint was
found, with only 39% of the 129 published RCTs being
consistent in all three parameters. Consistency of sample
size reporting was observed in only 55% of the
published RCTs.
The observed publication rate of Dutch investigator-
initiated RCT is higher than earlier reports.8,10-16 How-
ever, in this study, we found that approximately one out
of four Dutch RCTs remains unpublished after 5 years.
It seems unlikely that these results will ever be made
public. Investigators of these unpublished RCTs were
planning to recruit a total of 8850 patients. Although the
actual number of accrued patients in these unpublished
RCTs is unknown, a significant number of patients will
have been exposed to experimental treatments without
any attribution to clinical science. This is in breach of
the conditions to which agreement to participation by
informed consent was met. Previous investigations have
consistently shown that publication bias predominantly
affects negative results.21,22 There is evidence that non-
disclosure of trial results and consequential distortion of
evidence is harmful to patients.23 As an example, in the
case of the use of antiarrhythmic drugs for secondary
prevention of myocardial infarction, failure of timely
publication of negative results has been estimated to
have led to up to 75 000 preventable deaths a year in the
United States alone.24 Timely reporting of results is
essential to support evidence-based decision making by
FIGURE 1 Kaplan-Meier curve of publication rates of
randomized controlled trials across Dutch academic centers
(closing date 2011)
FIGURE 2 Time to publication of
results for completed randomized
controlled trials across (A) Dutch
academic centers and (B) topics (closing
date 2011) [Colour figure can be viewed
at wileyonlinelibrary.com]
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TABLE 2 Consistency in hypothesis, sample size, and primary endpoint of randomized controlled trials across Dutch academic centers
(closing date 2011)
Trials
Published N
Overall
Consistency
N (%)
Consistency
in Hypothesis
N (%)
Consistency in
Sample Size N
(%)
Consistency in
Primary
Endpoint N (%)
Discrepancy
in 3 Objects
(%)
Total 129 50 (39) 108 (84) 71 (55) 103 (80) 3 (2)
Center
I 24 11 (46) 21 (88) 12 (50) 19 (79) 1 (4)
II 21 10 (48) 18 (86) 15 (71) 17 (81) 0 (0)
III 15 6 (40) 13 (87) 9 (60) 11 (73) 0 (0)
IV 17 3 (14) 14 (82) 6 (35) 14 (82) 0 (0)
V 15 7 (47) 12 (80) 9 (60) 13 (87) 0 (0)
VI 8 2 (25) 6 (75) 4 (50) 5 (63) 1 (13)
VII 11 6 (55) 10 (91) 6 (55) 11 (100) 0 (0)
VIII 18 5 (28) 14 (78) 10 (56) 13 (72) 1 (6)
Study sites
Multicenter 51 24 (47) 43 (84) 33 (65) 42 (82) 0 (0)
Single center 78 26 (33) 65 (83) 38 (49) 61 (78) 3 (4)
Number of enrolled
patients
≤100 62 27 (44) 52 (84) 35 (56) 50 (81) 2 (3)
>100 67 23 (34) 56 (84) 36 (54) 53 (79) 1 (1)
Conditions studied
Nutritional and
metabolic
disorders
24 12 (50) 21 (88) 13 (54) 19 (79) 2 (8)
Behavior disorders 23 4 (17) 18 (78) 7 (30) 16 (70) 0 (0)
Cardiovascular
diseases
14 5 (36) 12 (86) 7 (50) 12 (86) 0 (0)
Cancer and other
neoplasms
16 9 (56) 11 (69) 12 (75) 15 (94) 0 (0)
Nervous system
diseases
7 4 (57) 6 (86) 5 (71) 6 (86) 0 (0)
Muscle, bone, and
cartilage diseases
6 2 (33) 4 (67) 4 (67) 3 (50) 1 (17)
Conditions of the
urinary tract,
sexual organs, and
pregnancy
6 2 (33) 4 (67) 5 (83) 4 (67) 0 (0)
Wounds and injuries 7 2 (29) 7 (100) 4 (57) 5 (71) 0 (0)
Viral diseases 5 3 (60) 5 (100) 3 (60) 5 (100) 0 (0)
Respiratory tract
diseases
1 1 (100) 1 (100) 1 (100) 1 (100) 0 (0)
Infectious diseases 2 0 (0) 2 (100) 1 (50) 1 (50) 0 (0)
Digestive system
diseases
2 1 (50) 2 (100) 2 (100) 1 (50) 0 (0)
Others 16 5 (31) 15 (94) 7 (44) 15 (94) 0 (0)
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clinicians and patients. Publishing results is also essen-
tial to allow more selective financing of trials and to pre-
vent waste of funds by avoiding financing of duplicate
trials that have proven to produce negative results in
the past.
In the present study, the principal investigators
reported several reasons for not publishing their results.
The most common reasons for not publishing were that
the RCT had not been started after trial registration or
was prematurely discontinued, or that the conduct of the
RCT was delayed. Slow patient recruitment is the most
common reason for delay. Little evidence is available on
strategies to improve recruitment to RCT.25 A realistic
sample size calculation that incorporates the incidence of
the studied condition as well as the amount of patients
that actually qualify for the trial according to the envis-
aged inclusion criteria could help to generate a feasible
trial protocol. In this respect, data on accrual of the same
patient population in previous trials conducted in the
same network would be supportive, since even with data
on incidence, most investigators overestimate accrual.
This implies that innovative tools are needed to improve
recruitment. For this purpose, tools that use trial registers
as a data repository could improve trial transparency and
accrual.26 Another reason for not publishing was that
finalized manuscripts were not accepted for publication
by medical journals. This implies that journals contribute
to publication bias, which is a known, longstanding but
unsolved problem.27,28 Publishing results is an ethical
obligation of researchers and editors. Withholding results
could have major consequences.28 Future studies could
determine additional factor associated with the non-
publication of clinical trials such as effect size and statis-
tical and clinical significance.
A potential solution could be to enable investigators
to submit trial results to a trial register. In this way,
regardless of publication of the manuscript, the trial
results are accessible to the public. However, it is cur-
rently not possible to submit study results in the NTR
other than in a plain text box. Another possible solution
is that research ethical committees could have a more
prominent role to ensure that trial results are published
by monitoring the conduct of a trial.29 An obligation
to register trials before data collection as a condition
for ethical approval or funding could enhance both quan-
tity and quality of registrations. This is especially impor-
tant since the prospective registration of clinical trials
may reduce research dissemination bias in clinical
research.30
The incomplete consistency in hypothesis, sample
size calculation, and primary endpoint are a continuous
matter of concern.6,8 Results of an RCT with discrepancy
in hypothesis, sample size calculation, or primary end-
point might be unreliable and biased. Changes in trial
protocol should be clearly reported and justified, as some
may be well substantiated.
Our study has some limitations. Firstly, only RCTs
that had a closing date in 2011 were selected. This period
was chosen to provide a sufficient window to publish
results while the relevance of results that are still not
published after 5 years decreases rapidly. Additionally,
only RCTs that were registered in the NTR, which is the
primary register of The Netherlands, were included; how-
ever, Dutch RCTs may also have been registered in other
registers such as clinicaltrials.gov or ISCRTN.com. Sec-
ondly, to find out whether an RCT was published, we
ultimately contacted the principal investigators of whom
only 51% responded, leaving 11% of the initial RCTs with-
out any information on reasons for nonpublication.
Finally, the delayed reporting of results may also be due
to the publication strategy of the authors, with delays
occurring after repeated rejection by journals, or due to
the required follow-up for the primary endpoint. How-
ever, when the required follow-up is not reached, it can
be debated whether the RCT is really closed and finished.
Also, it cannot be excluded that the results of some
unpublished studies were presented at conferences with-
out a final publication. Although some might consider
this sufficient, this is most often not sufficient to
completely review all aspects of clinical trial results.
Inversely, some clinical trials might be published but not
registered at all. These are not captured in the current
analysis, and therefore, the number of included trials
could be underestimated.
FIGURE 3 Rates of consistency in
hypothesis, sample size, and primary endpoint
of randomized controlled trials across Dutch
academic centers (closing date 2011) [Colour
figure can be viewed at wileyonlinelibrary.com]
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Recently, two national initiatives were launched in
order to facilitate researchers in the design, initiation,
and conduct of clinical trials: the Dutch Clinical Research
Foundation and Dutch Oncology Research Platform. The
possibilities to share research expertise and establish col-
laborations should reduce the difficulties encountered in
the conduct of clinical trials and help improve the timely
publication of trial results.31
In conclusion, in a sample of 168 investigator-
initiated academic RCT, the results of 77% were publi-
shed within 5 years. Although this is better than earlier
reports, still one out of four RCTs remains unpublished.
The observed low overall consistency is a matter of con-
cern. Publication rates and consistency should be fre-
quently studied to improve the conduction and reporting
of RCTs. Solutions are warranted to improve the trial
design, trial registration procedures, trial publication
rates, and consistency between the trial register and pub-
lication of a manuscript.
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